Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 153 entries
Sorted by: Best Match Show Resources per page
Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation.

Current genomics

Pérez-Campo FM, Riancho JA.
PMID: 27019612
Curr Genomics. 2015 Dec;16(6):368-83. doi: 10.2174/1389202916666150817202559.

Human Mesenchymal Stem Cells (hMSCs) have emerged in the last few years as one of the most promising therapeutic cell sources and, in particular, as an important tool for regenerative medicine of skeletal tissues. Although they present a more...

Cite
Pérez-Campo FM, Riancho JA. Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation. Curr Genomics. 2015;16(6):368-83doi: 10.2174/1389202916666150817202559.
Pérez-Campo, F. M., & Riancho, J. A. (2015). Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation. Current genomics, 16(6), 368-83. https://doi.org/10.2174/1389202916666150817202559
Pérez-Campo, Flor M, and Riancho, José A. "Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation." Current genomics vol. 16,6 (2015): 368-83. doi: https://doi.org/10.2174/1389202916666150817202559
Pérez-Campo FM, Riancho JA. Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation. Curr Genomics. 2015 Dec;16(6):368-83. doi: 10.2174/1389202916666150817202559. PMID: 27019612; PMCID: PMC4765524.
Copy Download .nbib Format: NLM
Enhancing survival, engraftment, and osteogenic potential of mesenchymal stem cells.

World journal of stem cells

García-Sánchez D, Fernández D, Rodríguez-Rey JC, Pérez-Campo FM.
PMID: 31692976
World J Stem Cells. 2019 Oct 26;11(10):748-763. doi: 10.4252/wjsc.v11.i10.748.

Mesenchymal stem cells (MSCs) are promising candidates for bone regeneration therapies due to their plasticity and easiness of sourcing. MSC-based treatments are generally considered a safe procedure, however, the long-term results obtained up to now are far from satisfactory....

Cite
García-Sánchez D, Fernández D, Rodríguez-Rey JC, et al. Enhancing survival, engraftment, and osteogenic potential of mesenchymal stem cells. World J Stem Cells. 2019;11(10):748-763doi: 10.4252/wjsc.v11.i10.748.
García-Sánchez, D., Fernández, D., Rodríguez-Rey, J. C., & Pérez-Campo, F. M. (2019). Enhancing survival, engraftment, and osteogenic potential of mesenchymal stem cells. World journal of stem cells, 11(10), 748-763. https://doi.org/10.4252/wjsc.v11.i10.748
García-Sánchez, Daniel, et al. "Enhancing survival, engraftment, and osteogenic potential of mesenchymal stem cells." World journal of stem cells vol. 11,10 (2019): 748-763. doi: https://doi.org/10.4252/wjsc.v11.i10.748
García-Sánchez D, Fernández D, Rodríguez-Rey JC, Pérez-Campo FM. Enhancing survival, engraftment, and osteogenic potential of mesenchymal stem cells. World J Stem Cells. 2019 Oct 26;11(10):748-763. doi: 10.4252/wjsc.v11.i10.748. PMID: 31692976; PMCID: PMC6828596.
Copy Download .nbib Format: NLM
Antiviral agents in the critically ill child.

Seminars in pediatric infectious diseases

Munoz FM.
PMID: 32336897
Semin Pediatr Infect Dis. 2000 Jan;11(1):35-42. doi: 10.1053/spid.0110035. Epub 2005 Nov 02.

The treatment for most viral infections in children primarily is supportive. Severe viral illnesses and significant secondary complications that require treatment in the intensive care unit may occur in immunocompromised patients and also in infants and children who were...

Cite
Munoz FM. Antiviral agents in the critically ill child. Semin Pediatr Infect Dis. 2005;11(1):35-42doi: 10.1053/spid.0110035.
Munoz, F. M. (2000). Antiviral agents in the critically ill child. Seminars in pediatric infectious diseases, 11(1), 35-42. https://doi.org/10.1053/spid.0110035
Munoz, Flor M. "Antiviral agents in the critically ill child." Seminars in pediatric infectious diseases vol. 11,1 (2000): 35-42. doi: https://doi.org/10.1053/spid.0110035
Munoz FM. Antiviral agents in the critically ill child. Semin Pediatr Infect Dis. 2000 Jan;11(1):35-42. doi: 10.1053/spid.0110035. Epub 2005 Nov 02. PMID: 32336897; PMCID: PMC7173155.
Copy Download .nbib Format: NLM
The Power of Connections: AAP COVID-19 ECHO Accelerates Responses During a Public Health Emergency.

Journal of public health management and practice : JPHMP

Bernstein HH, Calabrese T, Corcoran P, Flint LE, Munoz FM.
PMID: 34797247
J Public Health Manag Pract. 2022 Jan-Feb 01;28(1):E1-E8. doi: 10.1097/PHH.0000000000001466.

CONTEXT: Pediatric providers across the United States have sought guidance on how to care for the nation's children during the uncertain historic times of the COVID-19 pandemic. The health care community has been challenged by the unprecedented burden of...

Cite
Bernstein HH, Calabrese T, Corcoran P, et al. The Power of Connections: AAP COVID-19 ECHO Accelerates Responses During a Public Health Emergency. J Public Health Manag Pract. 2022;28(1):E1-E8doi: 10.1097/PHH.0000000000001466.
Bernstein, H. H., Calabrese, T., Corcoran, P., Flint, L. E., Munoz, F. M. (2022). The Power of Connections: AAP COVID-19 ECHO Accelerates Responses During a Public Health Emergency. Journal of public health management and practice : JPHMP, 28(1), E1-E8. https://doi.org/10.1097/PHH.0000000000001466
Bernstein, Henry H, et al. "The Power of Connections: AAP COVID-19 ECHO Accelerates Responses During a Public Health Emergency." Journal of public health management and practice : JPHMP vol. 28,1 (2022): E1-E8. doi: https://doi.org/10.1097/PHH.0000000000001466
Bernstein HH, Calabrese T, Corcoran P, Flint LE, Munoz FM. The Power of Connections: AAP COVID-19 ECHO Accelerates Responses During a Public Health Emergency. J Public Health Manag Pract. 2022 Jan-Feb 01;28(1):E1-E8. doi: 10.1097/PHH.0000000000001466. PMID: 34797247.
Copy Download .nbib Format: NLM
Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine.

World journal of stem cells

González-González A, García-Sánchez D, Dotta M, Rodríguez-Rey JC, Pérez-Campo FM.
PMID: 33505599
World J Stem Cells. 2020 Dec 26;12(12):1529-1552. doi: 10.4252/wjsc.v12.i12.1529.

Mesenchymal stem cells (MSCs) are the most frequently used stem cells in clinical trials due to their easy isolation from various adult tissues, their ability of homing to injury sites and their potential to differentiate into multiple cell types....

Cite
González-González A, García-Sánchez D, Dotta M, et al. Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. World J Stem Cells. 2020;12(12):1529-1552doi: 10.4252/wjsc.v12.i12.1529.
González-González, A., García-Sánchez, D., Dotta, M., Rodríguez-Rey, J. C., & Pérez-Campo, F. M. (2020). Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. World journal of stem cells, 12(12), 1529-1552. https://doi.org/10.4252/wjsc.v12.i12.1529
González-González, Alberto, et al. "Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine." World journal of stem cells vol. 12,12 (2020): 1529-1552. doi: https://doi.org/10.4252/wjsc.v12.i12.1529
González-González A, García-Sánchez D, Dotta M, Rodríguez-Rey JC, Pérez-Campo FM. Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. World J Stem Cells. 2020 Dec 26;12(12):1529-1552. doi: 10.4252/wjsc.v12.i12.1529. PMID: 33505599; PMCID: PMC7789121.
Copy Download .nbib Format: NLM
Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Valencia Deray KG, Hosek KE, Chilukuri D, Dunson JR, Spielberg DR, Swartz SJ, Spinner JA, Leung DH, Moulton EA, Munoz FM, Demmler-Harrison GJ, Bocchini CE.
PMID: 34467658
Am J Transplant. 2022 Jan;22(1):187-198. doi: 10.1111/ajt.16822. Epub 2021 Sep 12.

Despite prevention strategies, cytomegalovirus (CMV) remains a common infection in pediatric solid organ transplant recipients (SOTR). We sought to determine the frequency, associations with, and long-term outcomes of CMV DNAemia in pediatric SOTR. We performed a single-center retrospective cohort...

Cite
Valencia Deray KG, Hosek KE, Chilukuri D, et al. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant. 2021;22(1):187-198doi: 10.1111/ajt.16822.
Valencia Deray, K. G., Hosek, K. E., Chilukuri, D., Dunson, J. R., Spielberg, D. R., Swartz, S. J., Spinner, J. A., Leung, D. H., Moulton, E. A., Munoz, F. M., Demmler-Harrison, G. J., & Bocchini, C. E. (2022). Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 22(1), 187-198. https://doi.org/10.1111/ajt.16822
Valencia Deray, Kristen G, et al. "Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. 22,1 (2022): 187-198. doi: https://doi.org/10.1111/ajt.16822
Valencia Deray KG, Hosek KE, Chilukuri D, Dunson JR, Spielberg DR, Swartz SJ, Spinner JA, Leung DH, Moulton EA, Munoz FM, Demmler-Harrison GJ, Bocchini CE. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant. 2022 Jan;22(1):187-198. doi: 10.1111/ajt.16822. Epub 2021 Sep 12. PMID: 34467658.
Copy Download .nbib Format: NLM
The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.

Vaccine

Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, Thu Hoang HT, Holder B, Kampmann B, Kazi AM, Langley JM, Leuridan E, Madavan N, Maertens K, Maldonado H, Miller E, Munoz-Rivas FM, Omer SB, Pollard AJ, Rice TF, Rots N, Sundaram ME, Wanlapakorn N, Voysey M.
PMID: 34949496
Vaccine. 2021 Dec 21; doi: 10.1016/j.vaccine.2021.12.007. Epub 2021 Dec 21.

AIM: There are few reliable estimates of the half-lives of maternal antibodies to the antigens found in the primary series vaccines. We aimed to calculate the half-lives of passively acquired diphtheria, tetanus and pertussis (DTP) antibodies in infants. We...

Cite
Oguti B, Ali A, Andrews N, et al. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine. 2021;doi: 10.1016/j.vaccine.2021.12.007.
Oguti, B., Ali, A., Andrews, N., Barug, D., Anh Dang, D., Halperin, S. A., Thu Hoang, H. T., Holder, B., Kampmann, B., Kazi, A. M., Langley, J. M., Leuridan, E., Madavan, N., Maertens, K., Maldonado, H., Miller, E., Munoz-Rivas, F. M., Omer, S. B., Pollard, A. J., Rice, T. F., Rots, N., Sundaram, M. E., Wanlapakorn, N., & Voysey, M. (2021). The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine, . https://doi.org/10.1016/j.vaccine.2021.12.007
Oguti, Blanché, et al. "The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis." Vaccine vol. (2021). doi: https://doi.org/10.1016/j.vaccine.2021.12.007
Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, Thu Hoang HT, Holder B, Kampmann B, Kazi AM, Langley JM, Leuridan E, Madavan N, Maertens K, Maldonado H, Miller E, Munoz-Rivas FM, Omer SB, Pollard AJ, Rice TF, Rots N, Sundaram ME, Wanlapakorn N, Voysey M. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine. 2021 Dec 21; doi: 10.1016/j.vaccine.2021.12.007. Epub 2021 Dec 21. PMID: 34949496.
Copy Download .nbib Format: NLM
Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review.

medRxiv : the preprint server for health sciences

Ciapponi A, Bardach A, Mazzoni A, Alconada T, Anderson S, Argento FJ, Ballivian J, Bok K, Comandé D, Erbelding E, Goucher E, Kampmann B, Karron R, Munoz FM, Palermo MC, Parker EPK, Rodriguez Cairoli F, Santa MV, Stergachis A, Voss G, Xiong X, Zamora N, Zaraa S, Berrueta M, Buekens PM.
PMID: 34127978
medRxiv. 2021 Jun 06; doi: 10.1101/2021.06.03.21258283.

BACKGROUND: Pregnant women with COVID-19 are at an increased risk of severe COVID-19 illness as well as adverse pregnancy and birth outcomes. Many countries are vaccinating or considering vaccinating pregnant women with limited available data about the safety of...

Cite
Ciapponi A, Bardach A, Mazzoni A, et al. Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review. medRxiv. 2021;doi: 10.1101/2021.06.03.21258283.
Ciapponi, A., Bardach, A., Mazzoni, A., Alconada, T., Anderson, S., Argento, F. J., Ballivian, J., Bok, K., Comandé, D., Erbelding, E., Goucher, E., Kampmann, B., Karron, R., Munoz, F. M., Palermo, M. C., Parker, E. P. K., Rodriguez Cairoli, F., Santa, M. V., Stergachis, A., Voss, G., Xiong, X., Zamora, N., Zaraa, S., Berrueta, M., & Buekens, P. M. (2021). Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.06.03.21258283
Ciapponi, Agustín, et al. "Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.06.03.21258283
Ciapponi A, Bardach A, Mazzoni A, Alconada T, Anderson S, Argento FJ, Ballivian J, Bok K, Comandé D, Erbelding E, Goucher E, Kampmann B, Karron R, Munoz FM, Palermo MC, Parker EPK, Rodriguez Cairoli F, Santa MV, Stergachis A, Voss G, Xiong X, Zamora N, Zaraa S, Berrueta M, Buekens PM. Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review. medRxiv. 2021 Jun 06; doi: 10.1101/2021.06.03.21258283. PMID: 34127978; PMCID: PMC8202435.
Copy Download .nbib Format: NLM
SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Spinner JA, Julien CL, Olayinka L, Dreyer WJ, Bocchini CE, Munoz FM, Devaraj S.
PMID: 34911654
J Heart Lung Transplant. 2021 Nov 14; doi: 10.1016/j.healun.2021.11.001. Epub 2021 Nov 14.

BACKGROUND: BACKGROUND: There is a paucity of data regarding the antibody response to SARS-CoV-2 vaccination in children after solid organ transplant.METHODS: We retrospectively reviewed the SARS-CoV-2 Anti-Spike IgG antibodies measured following SARS-CoV-2 vaccination at our pediatric heart transplant (HTx)...

Cite
Spinner JA, Julien CL, Olayinka L, et al. SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. 2021;doi: 10.1016/j.healun.2021.11.001.
Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, . https://doi.org/10.1016/j.healun.2021.11.001
Spinner, Joseph A, et al. "SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report." The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation vol. (2021). doi: https://doi.org/10.1016/j.healun.2021.11.001
Spinner JA, Julien CL, Olayinka L, Dreyer WJ, Bocchini CE, Munoz FM, Devaraj S. SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. 2021 Nov 14; doi: 10.1016/j.healun.2021.11.001. Epub 2021 Nov 14. PMID: 34911654; PMCID: PMC8590844.
Copy Download .nbib Format: NLM
It Takes an Epidemic to Move a Village: Severe Pertussis Disease in Infants in the 21st Century.

Journal of the Pediatric Infectious Diseases Society

Englund JA, Munoz FM.
PMID: 26619467
J Pediatric Infect Dis Soc. 2013 Jun;2(2):183-5. doi: 10.1093/jpids/pit010. Epub 2013 Mar 14.

No abstract available.

Cite
Englund JA, Munoz FM. It Takes an Epidemic to Move a Village: Severe Pertussis Disease in Infants in the 21st Century. J Pediatric Infect Dis Soc. 2013;2(2):183-5doi: 10.1093/jpids/pit010.
Englund, J. A., & Munoz, F. M. (2013). It Takes an Epidemic to Move a Village: Severe Pertussis Disease in Infants in the 21st Century. Journal of the Pediatric Infectious Diseases Society, 2(2), 183-5. https://doi.org/10.1093/jpids/pit010
Englund, Janet A, and Munoz, Flor M. "It Takes an Epidemic to Move a Village: Severe Pertussis Disease in Infants in the 21st Century." Journal of the Pediatric Infectious Diseases Society vol. 2,2 (2013): 183-5. doi: https://doi.org/10.1093/jpids/pit010
Englund JA, Munoz FM. It Takes an Epidemic to Move a Village: Severe Pertussis Disease in Infants in the 21st Century. J Pediatric Infect Dis Soc. 2013 Jun;2(2):183-5. doi: 10.1093/jpids/pit010. Epub 2013 Mar 14. PMID: 26619467.
Copy Download .nbib Format: NLM
The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.

Vaccine

Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, Thu Hoang HT, Holder B, Kampmann B, Kazi AM, Langley JM, Leuridan E, Madavan N, Maertens K, Maldonado H, Miller E, Munoz-Rivas FM, Omer SB, Pollard AJ, Rice TF, Rots N, Sundaram ME, Wanlapakorn N, Voysey M.
PMID: 34949496
Vaccine. 2022 Jan 24;40(3):450-458. doi: 10.1016/j.vaccine.2021.12.007. Epub 2021 Dec 21.

AIM: There are few reliable estimates of the half-lives of maternal antibodies to the antigens found in the primary series vaccines. We aimed to calculate the half-lives of passively acquired diphtheria, tetanus and pertussis (DTP) antibodies in infants. We...

Cite
Oguti B, Ali A, Andrews N, et al. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine. 2021;40(3):450-458doi: 10.1016/j.vaccine.2021.12.007.
Oguti, B., Ali, A., Andrews, N., Barug, D., Anh Dang, D., Halperin, S. A., Thu Hoang, H. T., Holder, B., Kampmann, B., Kazi, A. M., Langley, J. M., Leuridan, E., Madavan, N., Maertens, K., Maldonado, H., Miller, E., Munoz-Rivas, F. M., Omer, S. B., Pollard, A. J., Rice, T. F., Rots, N., Sundaram, M. E., Wanlapakorn, N., & Voysey, M. (2022). The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine, 40(3), 450-458. https://doi.org/10.1016/j.vaccine.2021.12.007
Oguti, Blanché, et al. "The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis." Vaccine vol. 40,3 (2022): 450-458. doi: https://doi.org/10.1016/j.vaccine.2021.12.007
Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, Thu Hoang HT, Holder B, Kampmann B, Kazi AM, Langley JM, Leuridan E, Madavan N, Maertens K, Maldonado H, Miller E, Munoz-Rivas FM, Omer SB, Pollard AJ, Rice TF, Rots N, Sundaram ME, Wanlapakorn N, Voysey M. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine. 2022 Jan 24;40(3):450-458. doi: 10.1016/j.vaccine.2021.12.007. Epub 2021 Dec 21. PMID: 34949496.
Copy Download .nbib Format: NLM
Applicability of the GAIA Maternal and Neonatal Outcome Case Definitions for the Evaluation of Adverse Events Following Vaccination in Pregnancy in High-income Countries.

The Pediatric infectious disease journal

Watson G, Dodd C, Munoz FM, Eckert LO, Jones CE, Buttery JP, Yildirim IB, Kachikis A, Heath PT, Schlaudecker EP, Bond NH, Santarcangelo PL, Wilcox CR, Bellamy K, Elmontser M, Sienas L, Simon R, Khalil A, Townsend R, Sturkenboom M, Black S.
PMID: 34596623
Pediatr Infect Dis J. 2021 Dec 01;40(12):1127-1134. doi: 10.1097/INF.0000000000003261.

BACKGROUND: The Brighton Collaboration Global Alignment of Immunization Safety in Pregnancy (GAIA) project developed case definitions for the assessment of adverse events in mothers and infants following maternal immunization. This study evaluated the applicability of these definitions to data...

Cite
Watson G, Dodd C, Munoz FM, et al. Applicability of the GAIA Maternal and Neonatal Outcome Case Definitions for the Evaluation of Adverse Events Following Vaccination in Pregnancy in High-income Countries. Pediatr Infect Dis J. 2021;40(12):1127-1134doi: 10.1097/INF.0000000000003261.
Watson, G., Dodd, C., Munoz, F. M., Eckert, L. O., Jones, C. E., Buttery, J. P., Yildirim, I. B., Kachikis, A., Heath, P. T., Schlaudecker, E. P., Bond, N. H., Santarcangelo, P. L., Wilcox, C. R., Bellamy, K., Elmontser, M., Sienas, L., Simon, R., Khalil, A., Townsend, R., Sturkenboom, M., & Black, S. (2021). Applicability of the GAIA Maternal and Neonatal Outcome Case Definitions for the Evaluation of Adverse Events Following Vaccination in Pregnancy in High-income Countries. The Pediatric infectious disease journal, 40(12), 1127-1134. https://doi.org/10.1097/INF.0000000000003261
Watson, Gabriella, et al. "Applicability of the GAIA Maternal and Neonatal Outcome Case Definitions for the Evaluation of Adverse Events Following Vaccination in Pregnancy in High-income Countries." The Pediatric infectious disease journal vol. 40,12 (2021): 1127-1134. doi: https://doi.org/10.1097/INF.0000000000003261
Watson G, Dodd C, Munoz FM, Eckert LO, Jones CE, Buttery JP, Yildirim IB, Kachikis A, Heath PT, Schlaudecker EP, Bond NH, Santarcangelo PL, Wilcox CR, Bellamy K, Elmontser M, Sienas L, Simon R, Khalil A, Townsend R, Sturkenboom M, Black S. Applicability of the GAIA Maternal and Neonatal Outcome Case Definitions for the Evaluation of Adverse Events Following Vaccination in Pregnancy in High-income Countries. Pediatr Infect Dis J. 2021 Dec 01;40(12):1127-1134. doi: 10.1097/INF.0000000000003261. PMID: 34596623.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 153 entries